AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8262820 — intervention group
Group type: EXPERIMENTAL
Intervention: LSA2L2 chemotherapy with 1800 cGy cranial irradiation and 1500 cGy to nonabdominal bulk disease
Number of subjects: 308
Study 8262820 — intervention group
Group type: COMPARATOR
Intervention: Reg B without cranial irradiation
Number of subjects: 308
Study 8262820 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiation for Regimen B and C patients with large mediastinal masses
Number of subjects: 308
Study 8262820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial fields encompassing the entire meningeal surface
Number of subjects: 308
Study 3897345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 374
Study 3897345 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 374
Study 3897345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 29793484 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients (TBR: 1.90 ± 0.38, aPWV: 9.9 ± 2.6 m/s)
Number of subjects: 121
Study 29793484 — intervention group
Group type: EXPERIMENTAL
Intervention: α1ATD-COPD patients (TBR: 1.94 ± 0.43, aPWV: 9.5 ± 1.8 m/s)
Number of subjects: 121
Study 29793484 — intervention group
Group type: COMPARATOR
Intervention: Smokers (TBR: 1.74 ± 0.30, aPWV: 7.8 ± 1.8 m/s)
Number of subjects: 121
Study 29793484 — intervention group
Group type: COMPARATOR
Intervention: Never-smokers (TBR: 1.71 ± 0.34, aPWV: 7.9 ± 1.7 m/s)
Number of subjects: 121
Study 27552838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic K‐file
Number of subjects: 72
Study 27552838 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrisafe file
Number of subjects: 72
Study 27552838 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth wire
Number of subjects: 72
Study 27552838 — intervention group
Group type: COMPARATOR
Intervention: No activation (group D)
Number of subjects: 72
Study 27552838 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation time
Number of subjects: 72
Study 24568874 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended sensorimotor experience with the objects
Number of subjects: 60
Study 24568874 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief sensorimotor experience with the objects
Number of subjects: 60
Study 24568874 — intervention group
Group type: COMPARATOR
Intervention: Reading written information about the objects' weights
Number of subjects: 60
Study 22222856 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg BHT-3009
Number of subjects: 155
Study 22222856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 22222856 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg BHT-3009
Number of subjects: 155
Study 20212267 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss via a hypocaloric diet
Number of subjects: 36
Study 18567749 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg isoflavones (ISO)
Number of subjects: 22
Study 18567749 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 22
Study 16020596 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 49
Study 16020596 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 49
Study 16020596 — intervention group
Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 49
Study 16020596 — intervention group
Group type: EXPERIMENTAL
Intervention: II genotype
Number of subjects: 49
Study 14643954 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) with a fraction dose of 1.8 Gy to a median total dose of 54 Gy
Number of subjects: 33
Study 14643954 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 33
Study 10471608 — intervention group
Group type: EXPERIMENTAL
Intervention: p55‐IgG, 0.083 mg/kg
Number of subjects: 165
Study 10471608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 8760850 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible light-cured fluoride-releasing material
Number of subjects: 50
Study 8760850 — intervention group
Group type: COMPARATOR
Intervention: Chemically cured nonfluoride resin
Number of subjects: 50
Study 8760850 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall evaluation of white spots
Number of subjects: 50
Study 1657199 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (0.15 mg)
Number of subjects: 25
Study 1657199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 6401510 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term maintenance treatment with cimetidine
Number of subjects: 44
Study 6401510 — intervention group
Group type: COMPARATOR
Intervention: Proximal gastric vagotomy
Number of subjects: 44
Study 30887953 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed work pattern
Number of subjects: 1045
Study 30887953 — intervention group
Group type: COMPARATOR
Intervention: 12/24 h work pattern
Number of subjects: 1045
Study 30887953 — intervention group
Group type: COMPARATOR
Intervention: 2 day/night shifts
Number of subjects: 1045
Study 30887953 — intervention group
Group type: COMPARATOR
Intervention: Single day shift
Number of subjects: 1045
Study 27880011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic Repair (37% phosphoric acid + Monobond‐S + Heliobond + Tetric N Ceram)
Number of subjects: 0
Study 27880011 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Repair (40% phosphoric acid + mixture of Clearfil Porcelain Bond Activator and Clearfil SE Bond Primer + Clearfil SE Bond + Filtek Z250)
Number of subjects: 0
Study 26883504 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention (home-based exercise program 3 times a week + physical therapy once every 2 weeks for 14 weeks)
Number of subjects: 30
Study 26883504 — intervention group
Group type: COMPARATOR
Intervention: Usual care physical therapy (physical therapy twice a week + home-based exercise program once a week for 14 weeks)
Number of subjects: 30
Study 26883504 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 30
Study 26883504 — intervention group
Group type: COMPARATOR
Intervention: Usual care physical therapy
Number of subjects: 30
Study 25028463 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin regimen (M, H, R, Z, E)
Number of subjects: 780
Study 25028463 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (RHZE thrice weekly)
Number of subjects: 780
Study 22591731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis of eating disorder symptoms and personality characteristics
Number of subjects: 70
Study 19781902 — intervention group
Group type: EXPERIMENTAL
Intervention: OffPCABG
Number of subjects: 81
Study 19781902 — intervention group
Group type: COMPARATOR
Intervention: OnPCABG
Number of subjects: 81
Study 17513285 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitored clinical care
Number of subjects: 45
Study 17513285 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 45
Study 17513285 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 16148461 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole prophylaxis
Number of subjects: 626
Study 16148461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 626
Study 11827839 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive form A (50 questions)
Number of subjects: 194
Study 11827839 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter form B (37 questions)
Number of subjects: 194
Study 10102058 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 1.0 IU/kg/week
Number of subjects: 30
Study 10102058 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 1.5 IU/kg/week
Number of subjects: 30
Study 10102058 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 0.5 IU/kg/week (first year), 0.75 IU/kg/week (second year), 1.0 IU/kg/week (third year), 0.5 IU/kg/week (fourth year)
Number of subjects: 30
Study 10102058 — intervention group
Group type: COMPARATOR
Intervention: Control group GH 0.5 IU/kg/week
Number of subjects: 30
Study 10102058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols from the two studies
Number of subjects: 30
Study 7539544 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg glucagon
Number of subjects: 74
Study 7539544 — intervention group
Group type: COMPARATOR
Intervention: 40 mg hyoscine N-butyl bromide
Number of subjects: 74
Study 1970460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 1 mg i.v. with atracurium
Number of subjects: 44
Study 1970460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 1 mg i.v. during continuous relaxation with atracurium or vecuronium
Number of subjects: 44
Study 1970460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 1 mg i.v. at the end of anesthesia
Number of subjects: 44
Study 7019558 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution (0.1% - 0.5%)
Number of subjects: 50
Study 7019558 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine eye drops (1% - 4%)
Number of subjects: 50
Study 31677583 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management for people with epilepsy (SMART) program
Number of subjects: 120
Study 28651793 — intervention group
Group type: EXPERIMENTAL
Intervention: IM+oral therapy (intramuscular + daily oral)
Number of subjects: 231
Study 28651793 — intervention group
Group type: COMPARATOR
Intervention: Daily oral-only therapy
Number of subjects: 231
Study 25805436 — intervention group
Group type: EXPERIMENTAL
Intervention: WARP technique at 1.5T and 3T MRI
Number of subjects: 19
Study 25805436 — intervention group
Group type: COMPARATOR
Intervention: Standard sequences at 1.5T and 3T MRI
Number of subjects: 19
Study 25805436 — intervention group
Group type: EXPERIMENTAL
Intervention: WARP technique at 3T MRI
Number of subjects: 19
Study 24115797 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-care package
Number of subjects: 0
Study 24115797 — intervention group
Group type: COMPARATOR
Intervention: Community-care strategy
Number of subjects: 0
Study 21866096 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1018921 (0.5 to 280 mg)
Number of subjects: 25
Study 21866096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 21866096 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1018921
Number of subjects: 25
Study 19265025 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin daily for 6 weeks, then 20 mg from weeks 6 to 12
Number of subjects: 318
Study 19265025 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin daily for 6 weeks, then 20 mg from weeks 6 to 12
Number of subjects: 318
Study 19265025 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks, then 20 mg rosuvastatin from weeks 6 to 12
Number of subjects: 318
Study 18058850 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistate model
Number of subjects: 0
Study 18058850 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint longitudinal-survival model
Number of subjects: 0
Study 14973794 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump techniques (OPCAB group)
Number of subjects: 50
Study 14973794 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiopulmonary bypass (CPB group)
Number of subjects: 50
Study 11573665 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia plus epidural analgesia
Number of subjects: 30
Study 11573665 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 30
Study 9574890 — intervention group
Group type: EXPERIMENTAL
Intervention: High allergen content NRL gloves
Number of subjects: 109
Study 9574890 — intervention group
Group type: EXPERIMENTAL
Intervention: High allergen content NRL gloves with skin protection cream
Number of subjects: 109
Study 9574890 — intervention group
Group type: COMPARATOR
Intervention: Low allergen content NRL gloves
Number of subjects: 109
Study 9574890 — intervention group
Group type: EXPERIMENTAL
Intervention: Low allergen content NRL gloves with skin protection cream
Number of subjects: 109
Study 8166094 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary electric toothbrush (Rota‐dent) with standard fluoride toothpaste and 0.05% sodium fluoride rinse
Number of subjects: 90
Study 8166094 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrushing with standard fluoride toothpaste
Number of subjects: 90
Study 8166094 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrushing with standard fluoride toothpaste and daily use of a 0.05% sodium fluoride rinse
Number of subjects: 90
Study 3294442 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetohydroxamic acid
Number of subjects: 210
Study 3294442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 29630721 — intervention group
Group type: EXPERIMENTAL
Intervention: Yimitasvir phosphate 30 mg
Number of subjects: 24
Study 29630721 — intervention group
Group type: EXPERIMENTAL
Intervention: Yimitasvir phosphate 100 mg
Number of subjects: 24
Study 29630721 — intervention group
Group type: EXPERIMENTAL
Intervention: Yimitasvir phosphate 200 mg
Number of subjects: 24
Study 29630721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28025025 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone (1.25-20mg)
Number of subjects: 96
Study 28025025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 26594626 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa and STN-DBS
Number of subjects: 12
Study 26594626 — intervention group
Group type: EXPERIMENTAL
Intervention: STN-DBS
Number of subjects: 12
Study 26594626 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched healthy participants)
Number of subjects: 12
Study 26594626 — intervention group
Group type: EXPERIMENTAL
Intervention: PD patients
Number of subjects: 12
Study 21919119 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally Focused Therapy (EFT)
Number of subjects: 42
Study 21919119 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 42
Study 21514589 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol esters (3.0 g/d)
Number of subjects: 24
Study 21514589 — intervention group
Group type: COMPARATOR
Intervention: Control (no added plant stanols)
Number of subjects: 24
Study 17458395 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0
Study 14730218 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (CAM) 400 mg/day orally for 14 days prior to surgery and for 7 days following surgery, in addition to flomoxef
Number of subjects: 26
Study 14730218 — intervention group
Group type: COMPARATOR
Intervention: Flomoxef (control group) administered for 4-7 days following surgery
Number of subjects: 26
Study 11506400 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryonic dopamine cell implantation
Number of subjects: 40
Study 11506400 — intervention group
Group type: COMPARATOR
Intervention: Placebo surgery
Number of subjects: 40
Study 9563352 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho (self-curing resin-modified glass-ionomer cement)
Number of subjects: 60
Study 9563352 — intervention group
Group type: COMPARATOR
Intervention: System 1+ (composite resin)
Number of subjects: 60
Study 10150185 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine 1 mg.kg‐1
Number of subjects: 15
Study 10150185 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine 1.5 mg.kg‐1
Number of subjects: 15
Study 10150185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3067546 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205-502 (0.05 micrograms daily)
Number of subjects: 12
Study 3067546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3067546 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205-502
Number of subjects: 12
Study 29649795 — intervention group
Group type: EXPERIMENTAL
Intervention: HD combined with hemoperfusion (HD + HP)
Number of subjects: 40
Study 26698929 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN + MTX
Number of subjects: 222
Study 26698929 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 222
Study 26698929 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue ETN
Number of subjects: 222
Study 26698929 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinue ETN
Number of subjects: 222
Study 23832397 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC1992371A administered on days 1 and 8 (schedule 1)
Number of subjects: 92
Study 23832397 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC1992371A administered on days 1, 2, and 3 (schedule 2)
Number of subjects: 92
Study 23832397 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC1992371A administered on days 1-3 and 8-10 (schedule 3)
Number of subjects: 92
Study 23832397 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC1992371A
Number of subjects: 92
Study 23110951 — intervention group
Group type: COMPARATOR
Intervention: Flunixin meglumine (FM)
Number of subjects: 6
Study 23110951 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 6
Study 23110951 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 6
Study 20609183 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) at 1.8 g/day for 12 months
Number of subjects: 18
Study 20609183 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 biopsy-confirmed IgA nephropathy patients)
Number of subjects: 18
Study 18338758 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 277
Study 18338758 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 277
Study 16383032 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. infusion of 50 g/L CISS, 2,000 ml per day (Group A)
Number of subjects: 53
Study 16383032 — intervention group
Group type: COMPARATOR
Intervention: i.v. infusion of 50 g/L glucose, 2,000 ml per day (Group B)
Number of subjects: 53
Study 16383032 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 53
Study 16383032 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 53
Study 12394711 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng (900 mg, 3 times daily)
Number of subjects: 45
Study 12394711 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng
Number of subjects: 45
Study 12394711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 10088031 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine nasal spray (0.2 mg twice daily)
Number of subjects: 0
Study 10088031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7749531 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative autologous blood donation and intraoperative salvage using the Cell Saver
Number of subjects: 155
Study 7749531 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative salvage and retransfusion of wound drainage blood using the Solcotrans System
Number of subjects: 155
Study 7749531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative salvage using the Cell Saver
Number of subjects: 155
Study 7749531 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative autologous blood donation
Number of subjects: 155
Study 2259928 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate (800 mg per day)
Number of subjects: 172
Study 2259928 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose megestrol acetate (160 mg per day)
Number of subjects: 172
Study 2259928 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate
Number of subjects: 172
Study 2259928 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose megestrol acetate
Number of subjects: 172
Study 2259928 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 172
Study 42529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal LH-RH
Number of subjects: 88
Study 42529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 31486156 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 143749
Study 31486156 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal mortality
Number of subjects: 143749
Study 31486156 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal death
Number of subjects: 143749
Study 31486156 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of placental abruption
Number of subjects: 143749
Study 31486156 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Cesarean section
Number of subjects: 143749
Study 30723189 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground exoskeleton‐assisted gait training (OEAGT)
Number of subjects: 46
Study 27672116 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Number of subjects: 166
Study 27672116 — intervention group
Group type: COMPARATOR
Intervention: Centre-based rehabilitation
Number of subjects: 166
Study 25800345 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic criteria for immunoglobulin G4-related diseases
Number of subjects: 0
Study 23672359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group: Verified telephone numbers, obtained best contact times, and informed subjects of planned follow-up calls.
Number of subjects: 0
Study 23672359 — intervention group
Group type: COMPARATOR
Intervention: Control group: Telephone numbers obtained from registration materials without verification, subjects not informed of planned follow-up calls.
Number of subjects: 0
Study 23672359 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Intervention and Control)
Number of subjects: 0
Study 23672359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study 20427106 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional simulation using Surgicase CMF Materialise software
Number of subjects: 17
Study 20427106 — intervention group
Group type: COMPARATOR
Intervention: Condylectomy and condylar reconstruction using vertical sliding osteotomy without three-dimensional simulation
Number of subjects: 17
Study 19265745 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm plus microbicide (Acidform)
Number of subjects: 192